Thrombophilia: How To Test? How To Manage?

By Julie Hambleton, MD

Print This | TOC | Previous | Next

References

1. Heijboer H, Brandjes DPM, Buller HR, et al. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 1990; 323:1512–1516
2. DeStefano V, Finazzi G, Mannucci P. Inherited thrombophilia: pathogenesis, clinincal syndromes, and management. Blood 1996; 87:3531–3544
3. Investigation and management of heritable thrombophilia. Br J Haematol 2001; 114:512–528
4. Kyrle P, Minar E, Hirschl M, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000; 343:457–462
5. Eldor A. Thrombophilia, thrombosis and pregnancy. Thromb Haemost 2001; 86:104–111
6. Rosendaal F, Helmerhorst FM, Vandenbroucke JP. Oral contraceptives, hormone replacement therapy and thrombosis. Thromb Haemost 2001; 86:112–123
7. Ryan D, Crowther MA, Ginsberg JS, et al. Relation of factor V Leiden genotype to risk for acute deep venous thrombosis after joint replacement surgery. Ann Intern Med 1998; 128:270–276
8. Hirsh J, Lee AY. How we diagnose and treat deep vein thrombosis. Blood 2002; 99:102–110
9. Hyers T, Agnelli G, Hull RD, et al. Sixth ACCP Consensus Conference on Antithrombotic Therapy: antithrombotic therapy for venous thromboembolic disease. Chest 2001; 119:176S–193S
10. Agnelli G, Prandoni P, Santamaria MG, et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med 2001; 345:165–169
11. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340:901–907
12. Bauer K. The thrombophilias: well-defined risk factors with uncertain therapeutic implications. Ann Intern Med 2001; 135:367–373
13. Green D. Genetic hypercoagulability: screening should be an informed choice. Blood 2001; 98:20
14. Mannucci P. Genetic hypercoagulability: prevention suggests testing family members. Blood 2001; 98:21–22
15. Levine J, Branch W, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346:752–763
16. Kearon C, Crowther M, Hirsh J. Management of patients with hereditary hypercoagulable disorders. Annu Rev Med 2000; 51:169–185
17. DeStefano V, Martinelli I, Mannucci PM, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 1999; 341:801–806

Print This | TOC | Previous | Next

3300 Dundee Road • Northbrook, Illinois 60062-2348 • (847) 498-1400 • (800) 343-2227
Copyright ©1999-2008 American College of Chest Physicians. All Rights Reserved.
ACCP Privacy Policy | ACCP Web Site Terms of Use